July 15, 2010
TCW’s Bryan Whalen, Tad Rivelle to Discuss TCW Total Return Bond Fund on Conference Call
TCW’s Bryan Whalen, Tad Rivelle to Discuss TCW Total Return Bond Fund on Conference Call
LOS ANGELES, CA–(Marketwire – July 13, 2010) – The TCW Group (TCW), an international asset-management firm, invites you to participate in a conference call on Wednesday, July 14 with Bryan Whalen, portfolio manager of the TCW Total Return Bond Fund ( NASDAQ : TGLMX ) ( NASDAQ : TGMNX ). Also joining the call will be Tad Rivelle, TCW’s Chief Investment Officer for High-Grade Fixed Income.
Read more on Marketwire
Stocks fall slightly after mixed economic reports
(AP:NEW YORK) Stocks are falling slightly in early trading after a batch of economic reports showed economic growth remains tepid even as companies report strong earnings.
Read more on INO News
Keryx Biopharmaceuticals Receives Orphan Drug Designation For KRX-0401 (Perifosine) For The Treatment Of Neuroblastoma
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.
Read more on PharmaceuticalOnline
